This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Pilot Trial of Ondansetron in the Treatment of 8 Patients With Obsessive-Compulsive Disorder

William A. Hewlett, MD, PhD; Sabine P. Schmid, MA; and Ronald M. Salomon, MD

Published: September 15, 2003

Article Abstract

Method: Eight medication-free subjects with a DSM-IV diagnosis of OCD and a Yale-Brown Obsessive Compulsive Scale (YBOCS) score >= 16 entered an 8-week open-label trial of ondansetron at a fixed dose of 1 mg 3 times daily in a study conducted between February and October 1998.

Results: Six subjects completed the trial. Three subjects (37%) achieved a clinically significant response (>= 35% reduction in YBOCS score). For these subjects, the average reduction in YBOCS-rated symptoms was 55%. In aggregate, the 8 patients exhibited a 28% reduction in YBOCS-rated symptoms over the course of the trial. The medication was well tolerated.

Conclusion: These results suggest that low-dose ondansetron may have promise as a monotherapy for some patients suffering from OCD.

Volume: 64

Quick Links: Obsessive-Compulsive and Related Disorders

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...